OBJECTIVE: Myeloperoxidase (MPO) is an enzyme expressed in neutrophils that is involved in tissue damage in inflammatory renal diseases. A functional G to A single-nucleotide polymorphism (SNP) is present at position -463 of the MPO promoter region and is associated with altered MPO expression. We hypothesized that the G-463A MPO SNP is a risk factor for developing lupus nephritis (LN) due to its potential influence on the inflammatory response. METHODS: DNA from 229 patients with SLE and 277 controls from the Carolina Lupus cohort, 58 African American patients from the Sea Island Lupus Cohort, and 51 African American patients from the Lupus Multiplex Registry and Repository were genotyped by PCR. A linear regression model was used to examine relationships between the MPO genotype, case/control status, demographic characteristics, and LN. RESULTS: There was no association of MPO genotype with systemic lupus erythematosus (SLE). However, the odds of developing LN were significantly higher among those with an A allele, compared to those without, in African American cases of all 3 cohorts. When the likelihood of developing LN was compared across MPO genotypes, the risk of developing LN was significantly higher among cases with a GA genotype versus GG (OR 2.11, 95% CI 1.12 to 3.97) and even higher with AA versus GG (OR 3.52, 95% CI 1.41 to 8.77). CONCLUSION: While the G-463A MPO SNP is not a risk factor for developing SLE, the low expressing A allele is a significant risk factor for developing LN that is gene dosage-dependent in African Americans.
OBJECTIVE:Myeloperoxidase (MPO) is an enzyme expressed in neutrophils that is involved in tissue damage in inflammatory renal diseases. A functional G to A single-nucleotide polymorphism (SNP) is present at position -463 of the MPO promoter region and is associated with altered MPO expression. We hypothesized that the G-463AMPO SNP is a risk factor for developing lupus nephritis (LN) due to its potential influence on the inflammatory response. METHODS: DNA from 229 patients with SLE and 277 controls from the Carolina Lupus cohort, 58 African American patients from the Sea Island Lupus Cohort, and 51 African American patients from the Lupus Multiplex Registry and Repository were genotyped by PCR. A linear regression model was used to examine relationships between the MPO genotype, case/control status, demographic characteristics, and LN. RESULTS: There was no association of MPO genotype with systemic lupus erythematosus (SLE). However, the odds of developing LN were significantly higher among those with an A allele, compared to those without, in African American cases of all 3 cohorts. When the likelihood of developing LN was compared across MPO genotypes, the risk of developing LN was significantly higher among cases with a GA genotype versus GG (OR 2.11, 95% CI 1.12 to 3.97) and even higher with AA versus GG (OR 3.52, 95% CI 1.41 to 8.77). CONCLUSION: While the G-463AMPO SNP is not a risk factor for developing SLE, the low expressing A allele is a significant risk factor for developing LN that is gene dosage-dependent in African Americans.
Authors: Lawrence W Castellani; James J Chang; Xuping Wang; Aldons J Lusis; Wanda F Reynolds Journal: J Lipid Res Date: 2006-04-25 Impact factor: 5.922
Authors: D L Lefkowitz; E Roberts; K Grattendick; C Schwab; R Stuart; J Lincoln; R C Allen; N Moguilevsky; A Bollen; S S Lefkowitz Journal: Cell Immunol Date: 2000-05-25 Impact factor: 4.868
Authors: M L Brennan; M M Anderson; D M Shih; X D Qu; X Wang; A C Mehta; L L Lim; W Shi; S L Hazen; J S Jacob; J R Crowley; J W Heinecke; A J Lusis Journal: J Clin Invest Date: 2001-02 Impact factor: 14.808
Authors: W F Reynolds; M Hiltunen; M Pirskanen; A Mannermaa; S Helisalmi; M Lehtovirta; I Alafuzoff; H Soininen Journal: Neurology Date: 2000-11-14 Impact factor: 9.910
Authors: Lixia Zeng; Anna V Mathew; Jaeman Byun; Kevin B Atkins; Frank C Brosius; Subramaniam Pennathur Journal: J Biol Chem Date: 2018-03-26 Impact factor: 5.157